Sagent Pharmaceuticals Director Frank Kung Sells 1,161,717 Shares (SGNT)
Sagent Pharmaceuticals (NASDAQ:SGNT) Director Frank Kung unloaded 1,161,717 shares of Sagent Pharmaceuticals stock on the open market in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $21.25, for a total value of $24,686,486.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on SGNT. Analysts at RBC Capital upgraded shares of Sagent Pharmaceuticals (NASDAQ:SGNT) from a “sector perform” rating to an “outperform” rating in a research note to investors on Wednesday, September 11th. They now have a $25.00 price target on the stock, up previously from $22.00. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Sagent Pharmaceuticals (NASDAQ:SGNT) from $18.00 to $21.00 in a research note to investors on Wednesday, August 7th.
Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $22.96.
Sagent Pharmaceuticals (NASDAQ:SGNT) traded up 0.74% during mid-day trading on Tuesday, hitting $23.13. The stock had a trading volume of 120,396 shares. Sagent Pharmaceuticals has a one year low of $13.39 and a one year high of $24.27. The stock has a 50-day moving average of $22.62 and a 200-day moving average of $19.54. The company has a market cap of $652.2 million and a price-to-earnings ratio of 33.28.
Sagent Pharmaceuticals (NASDAQ:SGNT) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.46 earnings per share for the quarter. The company had revenue of $59.60 million for the quarter, compared to the consensus estimate of $59.27 million. Analysts expect that Sagent Pharmaceuticals will post $0.86 EPS for the current fiscal year.
Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.